SOUTH SAN FRANCISCO, CA--(Marketwire - October 31, 2007) - Theravance, Inc. (NASDAQ: THRX) announced today that GSK has initiated a Phase 2 clinical study of GSK961081, an investigational bifunctional muscarinic antagonist-beta2 agonist compound for the treatment of chronic obstructive pulmonary disease (COPD). The compound was discovered by Theravance and is being developed by GlaxoSmithKline plc (GSK) under the parties’ Strategic Alliance Agreement.
